Patents by Inventor Anne-Christine Bay Jensen
Anne-Christine Bay Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230258659Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 1, 2022Publication date: August 17, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230251271Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 7, 2022Publication date: August 10, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230184787Abstract: Disclosed herein are immunoassay methods for detecting and quantifying human neutrophil elastase (HNE) generated fragments of calprotectin in a biofluid sample; and monoclonal antibodies and assay kits for use in such methods. The methods may be used for detecting, monitoring and/or determining the status or severity of a disease characterized by or exhibiting inflammation in a patient.Type: ApplicationFiled: May 12, 2021Publication date: June 15, 2023Applicant: Nordic Bioscience A/SInventors: Joachim Høg Mortensen, Dovile Sinkeviciute, Tina Manon-Jensen, Morten Asser Karsdal, Anne-Christine Bay-Jensen, Signe Holm Nielsen, Annika Hummersgaard Hansen, Jannie Marie Bülow Sand, Diana Julie Leeming, Nicholas Willumsen, Christina Jensen
-
Patent number: 11531028Abstract: An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting the biological sample with the antibody, and determining the amount of binding of the antibody.Type: GrantFiled: February 1, 2020Date of Patent: December 20, 2022Assignee: Nordic Bioscience A/SInventors: Anne Christine Bay-Jensen, Yi He, Morten Karsdal
-
Patent number: 11513128Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: GrantFiled: September 28, 2018Date of Patent: November 29, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Patent number: 11467169Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: GrantFiled: September 28, 2018Date of Patent: October 11, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Publication number: 20220047674Abstract: The present invention relates to pharmacogenetics, more specifically to strategies involving biomarkers associated with the clinical response to a compound before or during treatment of a cartilage disorder, such as osteoarthritis. The present invention more particularly relates to the combination of JSW measurements and level of specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used in strategies such as patients' enrichment in clinical trials, patients' selection strategy before or during treatment or for adapting the treatment of a patient in the frame of treatments for cartilage disorder, such as osteoarthritis.Type: ApplicationFiled: September 9, 2019Publication date: February 17, 2022Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231680Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231681Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20200158726Abstract: An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting the biological sample with the antibody, and determining the amount of binding of the antibody.Type: ApplicationFiled: February 1, 2020Publication date: May 21, 2020Applicant: Nordic Bioscience A/SInventors: Anne Christine Bay-Jensen, Yi He, Morten Karsdal
-
Publication number: 20160123993Abstract: An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting said biological sample with said antibody, and determining the amount of binding of said antibody.Type: ApplicationFiled: May 9, 2014Publication date: May 5, 2016Applicant: Nordic Bioscience A/SInventors: Anne-Christine Bay Jensen, Yi He, Morten Karsdal